13F filer · CIK 1440771
Stonepine Capital Management, LLC
Bend, OR · filing since Q4 2015 · last filing Aug 17, 2026
Reported value
$177.3M
$-72.5M vs prior
Positions
87
New / sold out
25 / 21
Added / reduced
23 / 27
Turnover
28.5%
buys $60.8M · sells $148.1M
Top-10 weight
44.4%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | INSMED INCCALL | +40,000 | – | +$5.6M |
| New | ELOXX PHARMACEUTICALS INC | +397,160 | – | +$5.5M |
| New | ULTRAGENYX PHARMACEUTICAL INCALL | +200,000 | – | +$5.5M |
| New | MEDTRONIC PLCCALL | +50,000 | – | +$4.4M |
| New | INDIVIOR PHARMACEUTICALS INC | +100,000 | – | +$4.1M |
| New | ABBOTT LABORATORIESCALL | +40,000 | – | +$3.8M |
| New | BOSTON SCIENTIFIC CORPCALL | +50,000 | – | +$3.3M |
| New | BIOMARIN PHARMACEUTICAL INCCALL | +50,000 | – | +$3.1M |
| Added | EDESA BIOTECH INC | +426,439 | +1421.5% | +$3.0M |
| Added | SATELLOS BIOSCIENCE INC | +391,624 | +391.6% | +$3.0M |
38 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | SPDR SERIES TRUSTPUT | -400,000 | -100.0% | $-51.1M |
| Sold out | SPDR SERIES TRUSTCALL | -400,000 | -100.0% | $-51.1M |
| Reduced | ADMA BIOLOGICS INCCALL | -500,000 | -43.5% | $-6.1M |
| Sold out | TERNS PHARMACEUTICALS INCCALL | -100,000 | -100.0% | $-5.3M |
| Reduced | TENAX THERAPEUTICS INC | -315,200 | -32.3% | $-4.6M |
| Reduced | ZEVRA THERAPEUTICS INC | -221,299 | -46.1% | $-3.2M |
| Sold out | ESTABLISHMENT LABS HLDGS INCCALL | -50,000 | -100.0% | $-2.8M |
| Sold out | ALEXANDRIA REAL ESTATE EQ INCALL | -50,000 | -100.0% | $-2.3M |
| Sold out | ACADIA PHARMACEUTICALS INCCALL | -100,000 | -100.0% | $-2.2M |
| Sold out | XOMA ROYALTY CORPORATION | -69,500 | -100.0% | $-2.2M |
38 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | VERASTEM INCCOM NEW | 3,349,627 | $12.8M | 7.22% |
| 2 | EVOLUS INCCOM | 1,590,162 | $11.0M | 6.23% |
| 3 | TENAX THERAPEUTICS INCCOM NEW | 660,000 | $9.6M | 5.42% |
| 4 | NEKTAR THERAPEUTICSCOM NEW | 120,654 | $8.4M | 4.75% |
| 5 | ADMA BIOLOGICS INCCALLCOM | 650,000 | $8.0M | 4.48% |
| 6 | ADMA BIOLOGICS INCCOM | 740,000 | $6.2M | 3.49% |
| 7 | CAMP4 THERAPEUTICS CORPCOM 13469V AB 4 CAMTEK LTD NOTE 12/0 | 1,389,622 | $6.1M | 3.43% |
| 8 | INSMED INCCALLCOM PAR $.01 | 40,000 | $5.6M | 3.16% |
| 9 | ELOXX PHARMACEUTICALS INCCOM NEW | 397,160 | $5.5M | 3.11% |
| 10 | ULTRAGENYX PHARMACEUTICAL INCALLCOM | 200,000 | $5.5M | 3.10% |
77 more rows. Subscribe for $29/month to see every row, download the data and use the API.